课题基金 / 基金详情

Evaluating the Adverse Cognitive Effects of Medications

Evaluating the Adverse Cognitive Effects of Medications
评估药物对认知的不良影响
批准号:
9038206
负责人:
Noll L. Campbell
金额:
$14.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2019-03-31

项目摘要

项目成果

Noll L. Campbell的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):申请人:Noll坎贝尔,PharmD,FASCP,BCPP通过两个住院医师的老年药物治疗专业培训开始了他的职业生涯,并拥有超过10年的临床经验。他对临床研究的兴趣影响他与印第安纳州大学的老年临床研究人员建立了关系。这种关系导致开展了若干活动和取得了一些经验, 为坎贝尔博士未来从事老年临床研究奠定了基础。为了保护 由于没有时间进行研究活动并追求自己的职业目标,他转而与普渡大学药学院进行研究任命。在这个职业发展奖的支持下,他将通过教学和体验式培训练习培养临床试验设计,药物流行病学和生物统计学方面的技能。在完成指导职业发展奖后,坎贝尔博士将与未来的项目竞争校外资金,以最大限度地减少药物对老年人认知的不良影响。研究职业发展计划:该应用程序提出了课程工作,研究策略和导师小组提供的辅导活动。指导团队包括一名老龄化脑健康服务研究专家(Malaz Boustani博士);药物流行病学领导人(Mick Murray博士);生物统计学和流行病学专家(Sujuan Gao博士);以及神经心理学专家(Fred Unverzagt博士)。职业发展计划旨在实现候选人的长期职业目标:(1)培养临床试验设计,药物流行病学和生物统计学方面的技能,以支持改善老龄化大脑健康的研究职业;(2)获得必要的信息技术技能,以便在未来的研究中使用这一宝贵的资源。研究项目:先前描述药物对认知障碍影响的文献受到药物暴露和认知障碍测量不准确的限制。该项目建议通过使用药物暴露和神经心理学评估的连续和准确的措施来解决这些限制。本分析中纳入的人群包括患有认知障碍的老年人,由于可改变和不可改变的风险因素的显著负担,这些老年人具有患痴呆症的高风险。该人群参加了一项旨在确定痴呆症风险因素的观察性研究。研究队列在大型医疗保健系统中接受护理,该系统在大型医疗记录数据库中捕获所有活动,包括药物分配数据。同样,在4年前瞻性研究期间,每年进行一次神经心理学评估,作为认知功能的综合指标。这些结果将为未来的干预措施提供初步证据,旨在减少药物的不良认知影响,并最终改善衰老大脑的健康。
英文摘要
DESCRIPTION (provided by applicant): The Applicant: Noll Campbell, PharmD, FASCP, BCPP began his career by pursuing specialty training in geriatric pharmacotherapy through two residencies and has over 10 years of clinical experience. His interests in clinical research influenced him to establish a relationship with the geriatric clinical researchers at Indiana University. This relationship resulted in several activities and experiences that have provided the foundation for Dr. Campbell's future career in geriatric clinical research. In an effort to protect time for research activity and pursue his career goals, he transitioned to a research appointment with the Purdue University College of Pharmacy. With the support of this career development award he will develop skills in clinical trial design, pharmacoepidemiology, and biostatistics through didactic and experiential training exercises. Upon completion of the mentored career development award, Dr. Campbell will compete for extramural funding with future projects minimizing the adverse cognitive effects of medications among older adults. The Research Career Development Plan: This application proposes course work, a research strategy, and mentored activities provided by a panel of mentors. The mentoring team includes an expert in aging brain health services research (Dr. Malaz Boustani); a leader in pharmacoepidemiology (Dr. Mick Murray); an expert in biostatistics and epidemiology (Dr. Sujuan Gao); and an expert in neuropsychology (Dr. Fred Unverzagt). The career development plan intends to achieve the candidate's long-term career goals of: (1) developing skills in clinical trial design, pharmacoepidemiology, and biostatistics to support a research career improving the health of the aging brain; and (2) obtaining information technology skills necessary to use this valuable resource in future research. The Research Project: Previous literature describing the impact of medications on cognitive impairment has been limited by inaccurate measurements of medication exposure and cognitive impairment. This project proposes to address these limitations by using continuous and accurate measures of medication exposure and neuropsychological assessments. The population included in this analysis consists of older adults with cognitive impairment who are at high risk of developing dementia due to a significant burden of modifiable and non-modifiable risk factors. This population was enrolled in an observational study aimed at identifying risk factors for dementia. The study cohort receives care within a large healthcare system that captures all activity in a large medical record database, including medication dispensing data. Similarly, neuropsychological assessments conducted annually during the four-year prospective period will be used as a comprehensive measure of cognitive function. These results will provide preliminary evidence for future interventions aimed at reducing the adverse cognitive effects of medications and ultimately improving the health of the aging brain.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Reducing Risk of Dementia through De-prescribing (R2D2)
  • 批准号:
    9922830
  • 项目类别:
  • 资助金额:
    $65.54万
  • 财政年份:
    2019
  • 负责人:
    Noll L. Campbell
  • 依托单位:
Reducing Risk of Dementia through De-prescribing (R2D2)
  • 批准号:
    10392349
  • 项目类别:
  • 资助金额:
    $64.27万
  • 财政年份:
    2019
  • 负责人:
    Noll L. Campbell
  • 依托单位:
Reducing Risk of Dementia through De-prescribing (R2D2)
  • 批准号:
    10605238
  • 项目类别:
  • 资助金额:
    $63.64万
  • 财政年份:
    2019
  • 负责人:
    Noll L. Campbell
  • 依托单位:
Evaluating the Adverse Cognitive Effects of Medications
  • 批准号:
    8635755
  • 项目类别:
  • 资助金额:
    $15.25万
  • 财政年份:
    2014
  • 负责人:
    Noll L. Campbell
  • 依托单位:
海外基金